Menu Search
Equities

Medipharm Labs Corp

  • Add to watchlist
  • Add to portfolio
  • Add an alert
LABS:TOR

Medipharm Labs Corp

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CAD)0.065
  • Today's Change-0.005 / -7.14%
  • Shares traded48.17k
  • 1 Year change-7.14%
  • Beta0.7638
Data delayed at least 15 minutes, as of Feb 09 2026 20:14 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Forecasts data is unavailable for this security.

Consensus recommendation

  • 20-Feb-25
  • 20-Nov-25
  • 18-Dec-25
  • 15-Jan-26
  • 05-Feb-26
Select bar for recommendation details.
Recommendations05-Feb-26
Buy0
Outperform0
Hold1
Sell0
Strong Sell0

Share price forecast in CAD

The one analyst offering a 12 month price target expects Medipharm Labs Corp share price to rise to 0.10 in the next year from the last price of 0.07.
High42.9%0.10
Med42.9%0.10
Low42.9%0.10

Earnings history & estimates in CAD

On Nov 13, 2025, Medipharm Labs Corp reported 3rd quarter 2025 losses of -0.01 per share. This result was in line with the expectation of the one analyst following the company and was the same as last year's 3rd quarter results.
The next earnings announcement is expected on Mar 30, 2026.
Average growth rate-202.50%
Medipharm Labs Corp reported annual 2024 losses of -0.03 per share on Mar 31, 2025.
Average growth rate+48.20%
More ▼

Revenue history & estimates in CAD

MediPharm Labs Corp. had 3rd quarter 2025 revenues of 12.22m. This bettered the 11.86m estimate of the one analyst covering the company. This was 25.04% above the prior year's 3rd quarter results.
Average growth rate+6.56%
MediPharm Labs Corp. had revenues for the full year 2024 of 45.21m. This was 36.73% above the prior year's results.
Average growth rate+12.09%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.